Physician profile
James W Christopher
NPI 1154301869
$9,110.80
in general payments reported to CMS, 2019-2025
17 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $177 · 2021: $247 · 2022: $248 · 2023: $712 · 2024: $6,497 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,734 · Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,734.00 |
| Food and Beverage | $1,523.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $7,100.45 | 2021-2025 | Affinity, Apligraf, Nushield |
| Senseonics, Incorporated | $800.00 | 2025 | Eversense |
| Intuitive Surgical, INC. | $330.01 | 2019-2024 | |
| Kerecis Limited | $181.82 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $170.16 | 2021-2025 | Transorb, Argyle, Progrip |
| Kowa Pharmaceuticals America, INC. | $90.11 | 2022-2023 | Seglentis |
| Zyla Life Sciences, INC. | $77.32 | 2020 | |
| Mimedx Group, INC. | $75.54 | 2024-2025 | |
| Tela Bio, INC. | $58.53 | 2023-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Aroa Biosurgery Incorporated | $56.08 | 2022-2023 | |
| Ascensia Diabetes Care US INC. | $50.76 | 2024-2025 | |
| Smith+Nephew, INC. | $32.74 | 2025 | Collagenase Santyl |
| Allergan, INC. | $20.37 | 2022 | |
| Becton, Dickinson and Company | $19.90 | 2023 | Phasix Mesh |
| Pacira Pharmaceuticals Incorporated | $17.55 | 2023 | Exparel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.01 | 2024 | |
| Kci USA, INC. | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.